Strategic Advisors LLC acquired a new position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT – Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 28,132 shares of the company’s stock, valued at approximately $474,000.
Several other hedge funds have also recently bought and sold shares of CLBT. Scalar Gauge Management LLC bought a new position in Cellebrite DI in the fourth quarter valued at approximately $5,914,000. Quarry LP bought a new position in Cellebrite DI in the fourth quarter valued at approximately $36,000. Quadrature Capital Ltd increased its stake in Cellebrite DI by 96.5% in the fourth quarter. Quadrature Capital Ltd now owns 256,402 shares of the company’s stock valued at $2,222,000 after acquiring an additional 125,913 shares during the last quarter. Counterpoint Mutual Funds LLC bought a new position in Cellebrite DI in the first quarter valued at approximately $657,000. Finally, Meritage Portfolio Management bought a new position in Cellebrite DI in the first quarter valued at approximately $272,000. 45.88% of the stock is currently owned by institutional investors and hedge funds.
Cellebrite DI Trading Down 0.1 %
CLBT stock traded down $0.02 during midday trading on Thursday, hitting $18.09. The stock had a trading volume of 401,333 shares, compared to its average volume of 1,123,635. Cellebrite DI Ltd. has a 1-year low of $6.36 and a 1-year high of $18.73. The firm has a market cap of $3.73 billion, a P/E ratio of -31.22, a price-to-earnings-growth ratio of 2.38 and a beta of 1.52. The business has a fifty day moving average price of $16.11 and a two-hundred day moving average price of $13.14.
Analyst Upgrades and Downgrades
CLBT has been the topic of a number of recent analyst reports. Needham & Company LLC lifted their price objective on shares of Cellebrite DI from $14.00 to $17.00 and gave the company a “buy” rating in a research note on Friday, August 16th. TD Cowen raised their target price on shares of Cellebrite DI from $20.00 to $23.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. JPMorgan Chase & Co. raised their target price on shares of Cellebrite DI from $14.00 to $15.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. Bank of America raised their target price on shares of Cellebrite DI from $13.00 to $17.00 and gave the company a “buy” rating in a research report on Friday, August 16th. Finally, Craig Hallum raised their target price on shares of Cellebrite DI from $20.00 to $23.00 and gave the company a “buy” rating in a research report on Wednesday, September 25th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $18.57.
Check Out Our Latest Research Report on Cellebrite DI
Cellebrite DI Profile
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Read More
- Five stocks we like better than Cellebrite DI
- Stock Market Sectors: What Are They and How Many Are There?
- MercadoLibre Targets Double-Digit Upside with Argentina Boom
- Best Stocks Under $5.00
- Domino’s Pizza Stock Delivers: A Hot Buy for Growth Investors
- 3 Warren Buffett Stocks to Buy Now
- 3 Small-Cap Stocks Ready to Deliver Significant Growth
Want to see what other hedge funds are holding CLBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellebrite DI Ltd. (NASDAQ:CLBT – Free Report).
Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.